Blood-based biomarkers for the diagnosis and monitoring of gliomas
- 1 September 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (9), 1155-1161
- https://doi.org/10.1093/neuonc/noy074
Abstract
Monitoring patient response to treatment is challenging for most cancers, but it is particularly difficult in glioblastoma multiform, the most common and aggressive form of malignant brain tumor. These tumors exhibit a high degree of heterogeneity which may not be reflected in a biopsy. To determine if the current standard of care is effective, glioma patients are monitored using MRI or CT scans, an effective but sometimes misleading approach due to the phenomenon of pseudoprogression. As such, there is incredible need for a minimally invasive "liquid biopsy" to assist in molecularly characterizing the tumors while also aiding in the identification of true progression in glioblastoma. This review details the status and potential impact for circulating tumor cells, extracellular vesicles, ctDNA, and ctRNA, putative circulating biomarkers found in the blood in glioblastoma patients. As mutation-based therapy becomes more prevalent in gliomas, blood-based analyses may offer a non-invasive method of identifying mutations. The ability to obtain serial "liquid biopsies" will provide unique opportunities to study the evolution of tumors and mechanisms of treatment resistance and monitor for mutational changes in response to therapy.Funding Information
- National Institutes of Health (EB002503)
- NIH National Institute of Biomedical Imaging and Bioengineering (EB012493)
- Wang Pediatric Brain Tumor Collaborative (EB002503)
This publication has 76 references indexed in Scilit:
- Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implicationsCancer, 2017
- Necessity Is the Mother of Invention: The Development of Digital GenomicsClinical Chemistry, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Control of glioblastoma tumorigenesis by feed-forward cytokine signalingNature Neuroscience, 2016
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patientsJournal of Applied Genetics, 2013
- Detection of IDH1 mutation in the plasma of patients with gliomaNeurology, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- MicroRNA-451 Regulates LKB1/AMPK Signaling and Allows Adaptation to Metabolic Stress in Glioma CellsMolecular Cell, 2010
- [Not Available].1948